Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

August 13, 2018

Study Completion Date

August 13, 2018

Conditions
HyperuricemiaAlbuminuriaType 2 Diabetes
Interventions
DRUG

Verinurad 9 mg+Febuxostat 80 mg

Capsule administered orally, once daily for 24 weeks

DRUG

Placebo

Capsule administered orally, once daily for 24 weeks

Trial Locations (18)

77058

Research Site, Houston

77070

Research Site, Houston

77478

Research Site, Sugar Land

77584

Research Site, Pearland

77598

Research Site, Webster

90017

Research Site, Los Angeles

90022

Research Site, Los Angeles

90036

Research Site, Los Angeles

90805

Research Site, Lakewood

91351

Research Site, Canyon Country

91606

Research Site, North Hollywood

91911

Research Site, Chula Vista

92025

Research Site, Escondido

92868

Research Site, Orange

92882

Research Site, Corona

95648

Research Site, Lincoln

95821

Research Site, Sacramento

92056-4510

Research Site, Oceanside

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY